

Disclosure of amyloid PET results to persons with subjective cognitive decline - an AMYPAD sub-study

Publishable Summary

In the frame of AMYPAD DPMS, the question of the disclosure of the amyloid PET result has been raised, especially within the SCD sub-population participating to the study. In order to assess the disclosure practices in the participating sites, an AMYPAD sub-study has been designed: Disclosure of amyloid PET results to persons with subjective cognitive decline - an AMYPAD sub-study.

This sub-study targets up to 300 SCD patients included in AMYPAD DPMS and aims at survey the communication practices of memory clinics to patients with SCD undergoing amyloid PET for risk profiling, and patient outcomes. The results of this study will help implementing amyloid PET for risk profiling of SCD patients in the clinic.

For more information: info@amypad.org

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

